2Arjun S, Ponni P. Recent developments in diagnosis of pancreatic cancer. Br Med J, 2004,329: 668-673.
3Magnani JL,Steplewski I,Koprowski H,et al. Idendification of the gastrointestinal and pancreatic cancer-associated antigen de- tected by monochnal antigenl9-9 in the sera of patients as a mucin. Cancer Res, 1983,43 (11) : 5489-5492.
5Rosty C,Goggins M. Early detection of pancreatic carcinoma. Hematoloneol Clin Am, 2002,16( 1 ) : 302-304.
6Szajda SD,Waszkiewlez N,Chojnowska S. Carbohydrate markers of pancreatic cancer. Bioehem Soe Trans, 2011,39( 1 ) : 340-343.
7Waraya M,Yamashita K,Katagiri H,et al. Preoperative serum CA19-9 and dissected pefipancreatic tissue margin as determin- ers of long-term survival in pancreatic cancer. Ana Surg Oncol, 2009,16(5) : 1231-1240.
8Kim JE,Lee KT,Lee JK,et al. Clinical usefulness of carbohy- drate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenteol Hepatol, 2004,19 ( 1 ) : 182-186.
二级参考文献39
1Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer, 1994, 70: 481-486.
2Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer, 1996,73: 372-376.
4Rozenblum E, Schutte M, Goggins M, et al. Tumorsuppressive pathways in pancreatic carcinoma. Cancer Res,1997, 57: 1731-1734.
5Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of K-ras, p53 and HER-2/neu expression in hyperplastic dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol,1999, 30: 123-129.
6Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg, 2002, 9: 39-44.
7Ha A, Watanabe H, Yamaguchi Y, et al. Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas, 2001, 23: 356-363.
8Kimura W, Zhao B, Futakawa N, et al. Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Hepatogastroenterology, 1999, 46 :532-539.
9Tateishi K, Tada M, Yamagata M, et al. Hight proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesion. Gut, 1999,45:737-740.
10Ruggeri B, Zhang SY, Caamano J, et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.Oncogene, 1992, 75 1503-1511.
2Jamal A, Siegel R, Xu J, et al. Cancer statistics 2010[J]. CA Cancer J Clin, 2010, 60(5) :277-300.
3Ye B, Gagnon A, Mok SC. Recent technical strategies to i- dentify diagnostic biomarkers for ovarian cancer[J']. Expert Rev Proteomics, 2007, 4(1):121-131.
4Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomar- kers in combination with CA125 for detection of epithelial o- varian cancer using prediagnestic serum samples from the Prostate, Lung. Colorectal, and Ovarian ( PLCO ) Cancer Screening Trial[J']. Cancer, 2012, 118(1) : 91-100.
5Morre RG, Brown MC, Miller MC, et al. The use of multi pie novel tumor biomarkers for the detection of ovarian car patients with a pelvic mass[-JJ. Gynecol Oncol 2008, 108(2):402-408.
